From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea.

The global CAR T-cell therapy market is projected to grow from USD 2.7 billion in 2025 to over USD 27.5 billion by 2033, reflecting a robust CAGR of 26.2%.

Treatment with UBX1325 resulted in vision gains comparable to aflibercept at weeks 24 and 36 in difficult-to-treat patient populationUBX1325 was ...

Health care companies rose as traders rotated back into high-risk biotech firms. Federal drug regulators missed the deadline for making a key decision regarding a Covid-19 vaccine from Novavax ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Researchers have successfully developed a novel drug to restore vision. The treatment method restores vision through retinal nerve regeneration.

Together, the companies will improve dental visualization and patient care with Biotech’s Scan4All intraoral scanners that feature OMNIVISION’s miniature camera modules SANTA CLARA ...

However, before helping create NeOnc’s potential treatments for biotech company NeOnc, Dr. Chen reflected on the many challenges that come with treating brain cancer. Historically, brain cancer ...